Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin in Cervicogenic Headache
NCT00184197Phase 2Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- May 2005
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cervicogenic headache (CGH) comparing Botox Sequence with Placebo Sequence (2 arms). Primary endpoint: Number of days with headache. Started May 2005; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cervicogenic headache (CGH)
Beyond the preview
Go deeper on NCT00184197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184197.